Surgical and interventional management of mitral valve regurgitation: A position statement from the European society of cardiology working groups on cardiovascular surgery and valvular heart disease

Michele De Bonis, Nawwar Al-Attar, Manuel Antunes, Michael Borger, Filip Casselman, Volkmar Falk, Thierry Folliguet, Bernard Iung, Patrizio Lancellotti, Salvatore Lentini, Francesco Maisano, David Messika-Zeitoun, Claudio Muneretto, Phillipe Pibarot, Luc Pierard, Prakash Punjabi, Raphael Rosenhek, Piotr Suwalski, Alec Vahanian, Olaf WendlerBernard Prendergast

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Surgical and interventional treatment for mitral regurgitation (MR) requires a multidisciplinary approach. Experienced operators in high volume centers with a dedicated Heart Team obtain best outcomes. • Surgical repair is the reference standard treatment in primary MR. Timely surgery is associated with excellent outcome and restoration of normal life expectancy. Percutaneous procedures should be reserved for high-risk or inoperable symptomatic patients. • The choice of treatment in secondary MR is more controversial: - Surgical correction can improve symptoms and quality of life, and reverse left ventricular (LV) remodelling in selected patients. However, a clear prognostic benefit in comparison with optimal medical therapy has not been demonstrated. Undersized annuloplasty might offer a satisfactory result if performed before the onset of severe LV dilatation and in the absence of echocardiographic predictors of postoperative residual or recurrent MR. Otherwise, mitral valve (MV) replacement with preservation of the sub-valvular apparatus is preferable. - Percutaneous edge-to-edge (EE) repair for secondary MR is a low-risk option to reduce symptoms and induce reverse LV remodelling but is commonly associated with residual and recurrent MR. The procedure should be reserved for patients who have significant symptoms despite optimal heart failure therapy (including cardiac resynchronisation where appropriate), are judged to be at excessive risk for MV surgery by a Heart Team, fulfil the echocardiographic criteria of eligibility, and do not have existing comorbidities to preclude the benefits of correction or reduction of MR. • Ongoing trials in patients with isolated secondary MR will define whether percutaneous EE repair has a significant role in the management of heart failure. • Randomized studies are needed to clarify whether correction of MR in high-risk patients provides clinical and prognostic benefit in comparison with optimal medical therapy.

Original languageEnglish
Pages (from-to)133-139
Number of pages7
JournalEuropean Heart Journal
Volume37
Issue number2
DOIs
Publication statusPublished - 2016

Fingerprint

Heart Valve Diseases
Mitral Valve Insufficiency
Cardiology
Ventricular Remodeling
Mitral Valve
Heart Failure
Therapeutics
Cardiac Resynchronization Therapy
Life Expectancy
Thoracic Surgery
Comorbidity
Dilatation
Quality of Life

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Surgical and interventional management of mitral valve regurgitation : A position statement from the European society of cardiology working groups on cardiovascular surgery and valvular heart disease. / De Bonis, Michele; Al-Attar, Nawwar; Antunes, Manuel; Borger, Michael; Casselman, Filip; Falk, Volkmar; Folliguet, Thierry; Iung, Bernard; Lancellotti, Patrizio; Lentini, Salvatore; Maisano, Francesco; Messika-Zeitoun, David; Muneretto, Claudio; Pibarot, Phillipe; Pierard, Luc; Punjabi, Prakash; Rosenhek, Raphael; Suwalski, Piotr; Vahanian, Alec; Wendler, Olaf; Prendergast, Bernard.

In: European Heart Journal, Vol. 37, No. 2, 2016, p. 133-139.

Research output: Contribution to journalArticle

De Bonis, M, Al-Attar, N, Antunes, M, Borger, M, Casselman, F, Falk, V, Folliguet, T, Iung, B, Lancellotti, P, Lentini, S, Maisano, F, Messika-Zeitoun, D, Muneretto, C, Pibarot, P, Pierard, L, Punjabi, P, Rosenhek, R, Suwalski, P, Vahanian, A, Wendler, O & Prendergast, B 2016, 'Surgical and interventional management of mitral valve regurgitation: A position statement from the European society of cardiology working groups on cardiovascular surgery and valvular heart disease', European Heart Journal, vol. 37, no. 2, pp. 133-139. https://doi.org/10.1093/eurheartj/ehv322
De Bonis, Michele ; Al-Attar, Nawwar ; Antunes, Manuel ; Borger, Michael ; Casselman, Filip ; Falk, Volkmar ; Folliguet, Thierry ; Iung, Bernard ; Lancellotti, Patrizio ; Lentini, Salvatore ; Maisano, Francesco ; Messika-Zeitoun, David ; Muneretto, Claudio ; Pibarot, Phillipe ; Pierard, Luc ; Punjabi, Prakash ; Rosenhek, Raphael ; Suwalski, Piotr ; Vahanian, Alec ; Wendler, Olaf ; Prendergast, Bernard. / Surgical and interventional management of mitral valve regurgitation : A position statement from the European society of cardiology working groups on cardiovascular surgery and valvular heart disease. In: European Heart Journal. 2016 ; Vol. 37, No. 2. pp. 133-139.
@article{fb2a1334fd614181ba025afee3897791,
title = "Surgical and interventional management of mitral valve regurgitation: A position statement from the European society of cardiology working groups on cardiovascular surgery and valvular heart disease",
abstract = "Surgical and interventional treatment for mitral regurgitation (MR) requires a multidisciplinary approach. Experienced operators in high volume centers with a dedicated Heart Team obtain best outcomes. • Surgical repair is the reference standard treatment in primary MR. Timely surgery is associated with excellent outcome and restoration of normal life expectancy. Percutaneous procedures should be reserved for high-risk or inoperable symptomatic patients. • The choice of treatment in secondary MR is more controversial: - Surgical correction can improve symptoms and quality of life, and reverse left ventricular (LV) remodelling in selected patients. However, a clear prognostic benefit in comparison with optimal medical therapy has not been demonstrated. Undersized annuloplasty might offer a satisfactory result if performed before the onset of severe LV dilatation and in the absence of echocardiographic predictors of postoperative residual or recurrent MR. Otherwise, mitral valve (MV) replacement with preservation of the sub-valvular apparatus is preferable. - Percutaneous edge-to-edge (EE) repair for secondary MR is a low-risk option to reduce symptoms and induce reverse LV remodelling but is commonly associated with residual and recurrent MR. The procedure should be reserved for patients who have significant symptoms despite optimal heart failure therapy (including cardiac resynchronisation where appropriate), are judged to be at excessive risk for MV surgery by a Heart Team, fulfil the echocardiographic criteria of eligibility, and do not have existing comorbidities to preclude the benefits of correction or reduction of MR. • Ongoing trials in patients with isolated secondary MR will define whether percutaneous EE repair has a significant role in the management of heart failure. • Randomized studies are needed to clarify whether correction of MR in high-risk patients provides clinical and prognostic benefit in comparison with optimal medical therapy.",
author = "{De Bonis}, Michele and Nawwar Al-Attar and Manuel Antunes and Michael Borger and Filip Casselman and Volkmar Falk and Thierry Folliguet and Bernard Iung and Patrizio Lancellotti and Salvatore Lentini and Francesco Maisano and David Messika-Zeitoun and Claudio Muneretto and Phillipe Pibarot and Luc Pierard and Prakash Punjabi and Raphael Rosenhek and Piotr Suwalski and Alec Vahanian and Olaf Wendler and Bernard Prendergast",
year = "2016",
doi = "10.1093/eurheartj/ehv322",
language = "English",
volume = "37",
pages = "133--139",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Surgical and interventional management of mitral valve regurgitation

T2 - A position statement from the European society of cardiology working groups on cardiovascular surgery and valvular heart disease

AU - De Bonis, Michele

AU - Al-Attar, Nawwar

AU - Antunes, Manuel

AU - Borger, Michael

AU - Casselman, Filip

AU - Falk, Volkmar

AU - Folliguet, Thierry

AU - Iung, Bernard

AU - Lancellotti, Patrizio

AU - Lentini, Salvatore

AU - Maisano, Francesco

AU - Messika-Zeitoun, David

AU - Muneretto, Claudio

AU - Pibarot, Phillipe

AU - Pierard, Luc

AU - Punjabi, Prakash

AU - Rosenhek, Raphael

AU - Suwalski, Piotr

AU - Vahanian, Alec

AU - Wendler, Olaf

AU - Prendergast, Bernard

PY - 2016

Y1 - 2016

N2 - Surgical and interventional treatment for mitral regurgitation (MR) requires a multidisciplinary approach. Experienced operators in high volume centers with a dedicated Heart Team obtain best outcomes. • Surgical repair is the reference standard treatment in primary MR. Timely surgery is associated with excellent outcome and restoration of normal life expectancy. Percutaneous procedures should be reserved for high-risk or inoperable symptomatic patients. • The choice of treatment in secondary MR is more controversial: - Surgical correction can improve symptoms and quality of life, and reverse left ventricular (LV) remodelling in selected patients. However, a clear prognostic benefit in comparison with optimal medical therapy has not been demonstrated. Undersized annuloplasty might offer a satisfactory result if performed before the onset of severe LV dilatation and in the absence of echocardiographic predictors of postoperative residual or recurrent MR. Otherwise, mitral valve (MV) replacement with preservation of the sub-valvular apparatus is preferable. - Percutaneous edge-to-edge (EE) repair for secondary MR is a low-risk option to reduce symptoms and induce reverse LV remodelling but is commonly associated with residual and recurrent MR. The procedure should be reserved for patients who have significant symptoms despite optimal heart failure therapy (including cardiac resynchronisation where appropriate), are judged to be at excessive risk for MV surgery by a Heart Team, fulfil the echocardiographic criteria of eligibility, and do not have existing comorbidities to preclude the benefits of correction or reduction of MR. • Ongoing trials in patients with isolated secondary MR will define whether percutaneous EE repair has a significant role in the management of heart failure. • Randomized studies are needed to clarify whether correction of MR in high-risk patients provides clinical and prognostic benefit in comparison with optimal medical therapy.

AB - Surgical and interventional treatment for mitral regurgitation (MR) requires a multidisciplinary approach. Experienced operators in high volume centers with a dedicated Heart Team obtain best outcomes. • Surgical repair is the reference standard treatment in primary MR. Timely surgery is associated with excellent outcome and restoration of normal life expectancy. Percutaneous procedures should be reserved for high-risk or inoperable symptomatic patients. • The choice of treatment in secondary MR is more controversial: - Surgical correction can improve symptoms and quality of life, and reverse left ventricular (LV) remodelling in selected patients. However, a clear prognostic benefit in comparison with optimal medical therapy has not been demonstrated. Undersized annuloplasty might offer a satisfactory result if performed before the onset of severe LV dilatation and in the absence of echocardiographic predictors of postoperative residual or recurrent MR. Otherwise, mitral valve (MV) replacement with preservation of the sub-valvular apparatus is preferable. - Percutaneous edge-to-edge (EE) repair for secondary MR is a low-risk option to reduce symptoms and induce reverse LV remodelling but is commonly associated with residual and recurrent MR. The procedure should be reserved for patients who have significant symptoms despite optimal heart failure therapy (including cardiac resynchronisation where appropriate), are judged to be at excessive risk for MV surgery by a Heart Team, fulfil the echocardiographic criteria of eligibility, and do not have existing comorbidities to preclude the benefits of correction or reduction of MR. • Ongoing trials in patients with isolated secondary MR will define whether percutaneous EE repair has a significant role in the management of heart failure. • Randomized studies are needed to clarify whether correction of MR in high-risk patients provides clinical and prognostic benefit in comparison with optimal medical therapy.

UR - http://www.scopus.com/inward/record.url?scp=84964632083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964632083&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehv322

DO - 10.1093/eurheartj/ehv322

M3 - Article

AN - SCOPUS:84964632083

VL - 37

SP - 133

EP - 139

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 2

ER -